Exelixis Inc Cash and Cash Equivalents
Exelixis Inc (EXEL) had Cash and Cash Equivalents of $281.45 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-07-03: Cash and Cash Equivalents, at Carrying Value $281.45M.
- 2026-04-03: Cash and Cash Equivalents, at Carrying Value $226.15M.
- 2026-01-02: Cash and Cash Equivalents, at Carrying Value $482.49M.
- 2025-10-03: Cash and Cash Equivalents, at Carrying Value $376.30M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-07-03 | $281.45M 10-Q · filed 2026-08-05 |
| 2026-04-03 | $226.15M 10-Q · filed 2026-05-05 |
| 2026-01-02 | $482.49M 10-Q · filed 2026-08-05 |
| 2025-10-03 | $376.30M 10-Q · filed 2025-11-04 |
| 2025-07-04 | $164.43M 10-Q · filed 2025-07-28 |
| 2025-04-04 | $183.75M 10-Q · filed 2025-05-13 |
| 2025-01-03 | $217.37M 10-K · filed 2026-02-10 |
| 2024-09-27 | $258.35M 10-Q · filed 2024-10-29 |
| 2024-06-28 | $198.46M 10-Q · filed 2024-08-06 |
| 2024-03-29 | $259.56M 10-Q · filed 2024-04-30 |
| 2023-12-29 | $262.99M 10-K · filed 2025-02-11 |
| 2023-09-29 | $396.86M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $464.48M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $540.60M 10-Q · filed 2023-05-09 |
| 2022-12-30 | $501.19M 10-K · filed 2024-02-06 |
| 2022-09-30 | $675.29M 10-Q · filed 2022-11-01 |
| 2022-07-01 | $627.00M 10-Q · filed 2022-08-09 |
| 2022-04-01 | $723.27M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $647.17M 10-K · filed 2023-02-07 |
| 2021-10-01 | $567.33M 10-Q · filed 2021-11-02 |
| 2021-07-02 | $492.46M 10-Q · filed 2021-08-05 |
| 2021-04-02 | $370.21M 10-Q · filed 2021-05-06 |
| 2021-01-01 | $319.22M 10-K · filed 2022-02-18 |
| 2020-10-02 | $334.05M 10-Q · filed 2020-11-05 |
| 2020-07-03 | $527.14M 10-Q · filed 2020-08-06 |
| 2020-04-03 | $357.34M 10-Q · filed 2020-05-05 |
| 2020-01-03 | $266.50M 10-K · filed 2021-02-11 |
| 2019-09-27 | $242.32M 10-Q · filed 2019-10-30 |
| 2019-06-28 | $369.79M 10-Q · filed 2019-07-31 |
| 2019-03-29 | $373.94M 10-Q · filed 2019-05-01 |
| 2018-12-28 | $314.77M 10-K · filed 2020-02-25 |
| 2018-09-28 | $353.62M 10-Q · filed 2019-10-30 |
| 2018-06-29 | $248.41M 10-Q · filed 2019-07-31 |
| 2018-03-30 | $232.33M 10-Q · filed 2019-05-01 |
| 2017-12-29 | $183.16M 10-K · filed 2020-02-25 |
| 2017-09-30 | $149.36M 10-Q · filed 2017-11-01 |
| 2017-09-29 | $149.36M 10-Q · filed 2018-11-01 |
| 2017-06-30 | $135.21M 10-Q · filed 2018-08-01 |
| 2017-03-31 | $183.18M 10-Q · filed 2018-05-02 |
| 2016-12-31 | $151.69M 10-Q · filed 2017-11-01 |
| 2016-12-30 | $151.69M 10-K · filed 2019-02-22 |
| 2016-09-30 | $111.22M 10-Q · filed 2017-11-01 |
| 2016-06-30 | $129.83M 10-Q · filed 2017-08-02 |
| 2016-03-31 | $276.88M 10-Q · filed 2017-05-01 |
| 2016-01-01 | $141.63M 10-K · filed 2018-02-26 |
| 2015-12-31 | $141.63M 10-Q · filed 2017-11-01 |
| 2015-09-30 | $145.64M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $61.95M 10-Q · filed 2016-08-03 |
| 2015-03-31 | $84.99M 10-Q · filed 2016-05-04 |
| 2015-01-02 | $80.39M 10-K · filed 2018-02-26 |
| 2014-12-31 | $80.39M 10-K · filed 2017-02-27 |
| 2014-09-30 | $100.06M 10-Q · filed 2015-11-10 |
| 2014-06-30 | $147.34M 10-Q · filed 2015-08-11 |
| 2014-03-31 | $157.54M 10-Q · filed 2015-04-30 |
| 2013-12-31 | $103.98M 10-K · filed 2017-02-27 |
| 2013-09-30 | $92.02M 10-Q · filed 2014-11-04 |
| 2013-06-30 | $131.77M 10-Q · filed 2014-07-31 |
| 2013-03-31 | $171.23M 10-Q · filed 2014-05-01 |
| 2012-12-31 | $170.07M 10-K · filed 2016-02-29 |
| 2012-09-30 | $308.81M 10-Q · filed 2013-10-30 |
| 2012-06-30 | $68.14M 10-Q · filed 2013-08-06 |
| 2012-03-31 | $70.47M 10-Q · filed 2013-05-07 |
| 2011-12-31 | $74.26M 10-K · filed 2015-03-02 |
| 2011-09-30 | $66.21M 10-Q · filed 2012-11-07 |
| 2011-06-30 | $75.28M 10-Q · filed 2012-08-02 |
| 2011-03-31 | $202.05M 10-Q · filed 2012-05-03 |
| 2010-12-31 | $97.44M 10-K · filed 2014-02-20 |
| 2010-09-30 | $95.34M 10-Q · filed 2011-10-27 |
| 2010-06-30 | $157.20M 10-Q · filed 2011-08-04 |
| 2009-12-31 | $86.80M 10-K · filed 2013-02-21 |
| 2008-12-31 | $247.70M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |